Ashley Tonsetic
Psychiatric/Mental Health · Grindstone, PANPI 1912669946
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,167 of the $11,474 with a category attached, or 88.6%. 22 manufacturers reported payments, led by AbbVie at 36.6% of the total. 2025 is the largest year on record at $3,441, more than ten times the $174 reported in 2021. Among psychiatric/mental health clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 619 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Neuronetics, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$898
- Otsuka America Pharmaceutical, Inc.$896
- Alkermes, Inc.$602
- Neurocrine Biosciences, Inc.$529
- plus $3K from 16 others
What the payments were for
- Travel & lodging$1,24811%
- Food & beverage$10,16789%
- Education$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 301 | $4,194 |
| Neuronetics, Inc. | 5 | $1,603 |
| Teva Pharmaceuticals USA, Inc. | 35 | $898 |
| Otsuka America Pharmaceutical, Inc. | 45 | $896 |
| Alkermes, Inc. | 29 | $602 |
| Neurocrine Biosciences, Inc. | 33 | $529 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 29 | $523 |
| Johnson & Johnson | 25 | $434 |
| Vanda Pharmaceuticals Inc. | 18 | $386 |
| Lundbeck LLC | 20 | $302 |
| Corium, LLC | 26 | $290 |
| Supernus Pharmaceuticals, Inc. | 15 | $242 |
| Sunovion Pharmaceuticals Inc. | 15 | $195 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $94 |
| Axsome Therapeutics, Inc. | 6 | $94 |
| Neos Therapeutics, LP | 4 | $67 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Tris Pharma Inc | 1 | $23 |
| Collegium Pharmaceutical, Inc. | 1 | $22 |
| Ironshore Pharmaceuticals Inc. | 1 | $19 |
| Alfasigma USA, Inc. | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEUROSTAR TMS THERAPY SYSTEM$1,506
- VRAYLAR$744
- REXULTI$156
- UZEDY$136
How this compares
$11,474 in reported general payments places this provider in the 95th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
See all psychiatric/mental health providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 152 | $222,388 |
| TrintellixVortioxetine Hydrobromide | 30 | $14,398 |
| Lurasidone Hcl | 40 | $13,803 |
| Clozapine OdtClozapine | 15 | $7,978 |
| VyvanseLisdexamfetamine Dimesylate | 21 | $7,342 |
| Vilazodone Hcl | 48 | $4,889 |
| Divalproex Sodium ErDivalproex Sodium | 26 | $3,785 |
| Atomoxetine Hcl | 36 | $3,231 |
| Perphenazine | 45 | $2,951 |
| Aripiprazole | 98 | $2,891 |
| Lisdexamfetamine Dimesylate | 13 | $2,754 |
| Mirtazapine | 170 | $2,514 |
| Duloxetine Hcl | 117 | $1,866 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 89 | $1,653 |
| Buspirone Hcl | 187 | $1,596 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $4,194 | $222,388152 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $94 | $21,74051 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
Other psychiatric/mental health in Grindstone
- Kimberly GarciaAllentown$573K
- Cortney SmithWashington$227K
- Britney KeplerPittsburgh$158K
- Kirstyn KamegBethel Park$136K
- Anna DipietroDowningtown$131K
- Deena MasciocchiLanghorne$71K
- Joseph GagnonChesterbrook$64K
- Michelle CohenWashington$62K
- Sharon KatzJenkintown$51K
- Jennifer BowmanCanonsburg$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.